TY - JOUR
T1 - Systematic review and meta-analysis of postexposure prophylaxis for crimean-congo hemorrhagic fever virus among healthcare workers
AU - Ergönül, Önder
AU - Keske, Şiran
AU - Çeldir, Melis Gökçe
AU - Kara, İlayda Arjen
AU - Pshenichnaya, Natalia
AU - Abuova, Gulzhan
AU - Blumberg, Lucille
AU - Gönen, Mehmet
N1 - Publisher Copyright:
© 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2018/9
Y1 - 2018/9
N2 - We performed a systematic review and meta-analysis on the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood or bodily fluids (odds ratio [OR] 4.2), being a nurse or physician (OR 2.1), and treating patients who died from CCHFV infection (OR 3.8) were associated with healthcare workers acquiring CCHFV infection; 7% of the workers who received postexposure prophylaxis (PEP) with ribavirin and 89% of those who did not became infected. PEP with ribavirin reduced the odds of infection (OR 0.01, 95% CI 0–0.03), and ribavirin use ≤48 hours after symptom onset reduced the odds of death (OR 0.03, 95% CI 0–0.58). The odds of death increased 2.4-fold every day without ribavirin treatment. Ribavirin should be recommended as PEP and early treatment for workers at medium-to-high risk for CCHFV infection.
AB - We performed a systematic review and meta-analysis on the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood or bodily fluids (odds ratio [OR] 4.2), being a nurse or physician (OR 2.1), and treating patients who died from CCHFV infection (OR 3.8) were associated with healthcare workers acquiring CCHFV infection; 7% of the workers who received postexposure prophylaxis (PEP) with ribavirin and 89% of those who did not became infected. PEP with ribavirin reduced the odds of infection (OR 0.01, 95% CI 0–0.03), and ribavirin use ≤48 hours after symptom onset reduced the odds of death (OR 0.03, 95% CI 0–0.58). The odds of death increased 2.4-fold every day without ribavirin treatment. Ribavirin should be recommended as PEP and early treatment for workers at medium-to-high risk for CCHFV infection.
UR - http://www.scopus.com/inward/record.url?scp=85052232486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052232486&partnerID=8YFLogxK
U2 - 10.3201/eid2409.171709
DO - 10.3201/eid2409.171709
M3 - Article
C2 - 30124196
AN - SCOPUS:85052232486
SN - 1080-6040
VL - 24
SP - 1642
EP - 1648
JO - Emerging infectious diseases
JF - Emerging infectious diseases
IS - 9
ER -